Speaker：Prof.Shaker A. Mousa, PhD, MBA, FACC, FACB
Time: Wednesday,10:00 a.m.,18th April
Over the past few years, evidence from the scientific and medical communities has demonstrated that nanotechnology and nanomedicine have tremendous potential to profoundly impact numerous aspects of cancer and other disorders in term of early diagnosis and targeted therapy. The utilization of nanotechnology for the development of new nano-carrier systems has the potential to offer improved chemotherapeutic delivery through increased solubility and sustained retention. One of the major advantages of this cutting edge technology is its unique multifunctional characteristics. Targeted delivery of drug incorporated nanoparticles, through conjugation of tumor-specific cell surface markers, such as tumor-specific antibodies or ligands, which can enhance the efficacy of the anticancer drug and reduce the side effects. Additionally, multifunctional characteristics of the nano-carrier system would allow for simultaneous imaging of tumor mass, targeted drug delivery and monitoring (Theranostics). A summary of recent progress in nanotechnology as it relates specifically to nanoparticles and anticancer drug delivery will be reviewed. Nano Nutraceuticals using combination of various natural products provide a great potential in diseases prevention. Additionally, various Nanomedicine approaches for the detection and treatment of various types of organ specific delivery, vascular targeting, and vaccine will be briefly discussed.
Shaker A. Mousa, PhD, MBA, FACC, FACB
Dr. Mousa was appointed as an endowed tenure Professor and Executive Vice President and Chairman of the Pharmaceutical Research Institute (PRI) in 2002 and Vice Provost for Research at ACPHS as of 2010. PRI is dedicated to education, research, and pharmaceutical services, focusing on drug discovery and drug development. Previously, Dr. Mousa a senior Scientist and fellow at DuPont Pharmaceutical Company for 17 years where he served as a Working Group chair of several drug discovery programs from 1985-2001. He also holds Adjunct Professor Appointments at Rensselaer Polytechnic Institute, SUNY Albany, and SUNY Buffalo. He is a Visiting Scholar at Johns Hopkins University. He holds over 350 US and International Patents discovering novel anti-angiogenesis strategies, antithrombotics, anti-integrins, anti-cancer, and non-invasive diagnostic imaging approaches. His has published more than 1,000 peer reviewed journal articles, book chapters, published issued patents, and books as editor and author. His research has focused on diagnostics and therapeutics of angiogenesis-related disorders, thrombosis, vascular and cardiovascular diseases using various technology platforms including Nanobiotechnology and cell therapeutics.
In his role as the founder and Chairman of PRI, Dr. Mousa works with several scientists (MD and/or PhD) and graduate students to identify novel strategies for unmet medical needs. At PRI, Dr, Mousa have developed partnerships with other academic research centers in New York State’s Capital Region as well as academic and industrial centers nationally and worldwide.
Dr. Mousa received his BS in Pharmacy from Alexandria University, College of Pharmacy & Pharmaceutical Sciences with distinction ranking number 1 on a class of over 500 Pharmacy students then he was appointed a member of the faculty where he received his MSC in Biochemical Pharmacology. Then he finished his PhD from Ohio State University, College of Medicine, Columbus, OH and Post-doctoral Fellowship, University of Kentucky, Lexington KY. He also received his MBA (Management) from Widener University, Chester, PA. He is a fellow of the American College of cardiology (FACC), fellow of the National Academy of Clinical Biochemistry (FACB), and Fellow of the American Heart Association (FAHA).